Roche's Inavolisib Receives Priority Review for Breast Cancer Treatment in China

In a significant development for breast cancer treatment in China, Roche's PI3K inhibitor, Inavolisib, has been granted priority review status by the National Medical Products Administration (NMPA). This milestone positions Inavolisib as a potential breakthrough therapy for patients with advanced breast cancer, particularly those with PIK3CA mutations, HR-positive/HER2-negative subtype. The approval would address a critical unmet need and usher in a new era of precision medicine for HR-positive breast cancer patients.

Roche's latest PI3K inhibitor, Inavolisib, is poised to become the first approved PI3K inhibitor in the field of breast cancer treatment in China. The compound has been granted priority review status by the NMPA, based on promising results from the pivotal Phase III INAVO120 study. The study evaluated the efficacy and safety of Inavolisib in combination with palbociclib and fulvestrant compared to palbociclib and fulvestrant alone in patients with PIK3CA-mutated HR-positive/HER2-negative advanced or metastatic breast cancer.

Results from the INAVO120 study demonstrated that the triple combination of Inavolisib, palbociclib, and fulvestrant significantly improved progression-free survival (PFS) compared to the control group(15.0 months vs. 7.3 months). Moreover, the risk of disease progression or death was reduced by 57% in the Inavolisib combination arm (HR=0.43, 95% CI 0.32-0.59; P<0.0001). The benefits of the triple therapy were consistent across various key subgroups, including different regions, pre- and post-menopausal status, presence of liver metastasis, and primary or acquired endocrine resistance.

Inavolisib's safety profile was favorable, with a low discontinuation rate and no new safety signals observed during the study. Although overall survival(OS)data are still maturing, a positive trend has been observed. The impressive efficacy and manageable safety of Inavolisib in combination with palbociclib and fulvestrant provide robust clinical evidence for its use as a first-line treatment option for patients with PIK3CA-mutated HR-positive/HER2-negative advanced breast cancer.

The prioritized review granted by the NMPA marks a significant step forward in expediting the evaluation and approval process for Inavolisib. This regulatory milestone holds the potential to transform the treatment landscape for HR-positive breast cancer patients in China, offering a precise, efficient, and safe therapeutic option. Approximately 40% of HR-positive/HER2-negative advanced breast cancer patients in clinical settings exhibit PIK3CA mutations. These patients often face poor prognosis and develop resistance to endocrine therapy and chemotherapy.

As a next-generation PI3Kα inhibitor, Inavolisib demonstrates high selectivity and exerts a dual mechanism of action by inhibiting PI3Kα and specifically degrading PI3Kα mutant proteins, leading to sustained pathway inhibition. This unique characteristic sets Inavolisib apart from other PI3K inhibitors. By preventing the accumulation of PIP3 and reducing downstream AKT signaling, Inavolisib effectively inhibits cell proliferation while minimizing systemic side effects associated with the inhibition of wild-type signaling.

The approval of Inavolisib would address an urgent clinical need and provide a breakthrough treatment option for HR-positive/HER2-negative advanced breast cancer patients with PIK3CA mutations. With HR-positive breast cancer accounting for approximately 70% of all breast cancer cases, the significance of the PI3K/AKT/mTOR pathway activation in breast cancer initiation, progression, and poor prognosis cannot be underestimated.

Roche's Inavolisib has received priority review status in China for the treatment of HR-positive/HER2-negative advanced breast cancer patients with PIK3CA mutations. This groundbreaking therapy has the potential to fill an unmet clinical need and revolutionize the treatment landscape, offering precise, efficient, and safe options for patients in need. The prioritized review by the NMPA signifies a significant step forward in the evaluation and approval process, paving the way for accelerated translation of research findings into clinical practice.